M6P Therapeutics Announces Presentation at the Upcoming 16th International Symposium of MPS and Related Diseases

- Oral Presentation on Friday, July 23, 2021 @ 11:25 a.m. ET / 17:25 p.m. CEST -

ST. LOUIS--(BUSINESS WIRE)--M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), announced today its participation at the 16^th International Symposium of MPS and Related Diseases, a research conference dedicated to the exchange of knowledge on mucopolysaccharidoses (MPS) and related syndromes, taking place virtually July 23-25, 2021.

Details related to M6PT’s oral presentation at MPS 2021 are below:

• Session Title: M002, a novel AAV9-mediated gene therapy in a mouse model of mucolipidosis type II
• Date: Friday, July 23, 2021
• Session Start Time: Approximately 11:25 a.m. ET / 17:25 p.m. CEST (4^th presentation during the session)

For event details, please visit: https://www.mps2021.com/index.php?idpagina=1&idioma=ang.

About M6P Therapeutics

M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation of targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics’ proprietary S1S3 bicistronic platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both recombinant enzyme and gene therapies, leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics’ team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of recombinant enzyme and gene therapies by harnessing the power of protein phosphorylation using its S1S3 bicistronic platform. M6P Therapeutics’ mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: www.m6ptherapeutics.com.